Camrelizumab

Generic Name
Camrelizumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1798286-48-2
Unique Ingredient Identifier
73096E137E
Background

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Indication

⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。

⑵用于霍奇金淋巴瘤(三线)、肝细胞癌(二线)、非鳞状非小细胞肺癌(一线联合)、食管鳞癌(二线)。

⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。

⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。

Associated Conditions
-
Associated Therapies
-

A SHR-1210 BE Study on Healthy Subjects

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-04-05
Last Posted Date
2023-09-14
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
118
Registration Number
NCT05799183
Locations
🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

First Posted Date
2023-03-29
Last Posted Date
2023-09-06
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
140
Registration Number
NCT05789043
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

First Posted Date
2023-03-16
Last Posted Date
2024-05-14
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
43
Registration Number
NCT05772273
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

First Posted Date
2023-03-16
Last Posted Date
2023-03-16
Lead Sponsor
Fudan University
Target Recruit Count
459
Registration Number
NCT05772208
Locations
🇨🇳

Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

First Posted Date
2023-03-09
Last Posted Date
2023-03-09
Lead Sponsor
Ying Lin
Target Recruit Count
66
Registration Number
NCT05761470
Locations
🇨🇳

First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

First Posted Date
2023-03-08
Last Posted Date
2024-02-06
Lead Sponsor
Fudan University
Target Recruit Count
223
Registration Number
NCT05760378
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

First Posted Date
2023-02-21
Last Posted Date
2023-11-29
Lead Sponsor
Hua Li
Target Recruit Count
22
Registration Number
NCT05738057
Locations
🇨🇳

The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

First Posted Date
2023-01-03
Last Posted Date
2023-01-03
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
184
Registration Number
NCT05669807

Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma

First Posted Date
2022-12-05
Last Posted Date
2022-12-05
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
23
Registration Number
NCT05637268
Locations
🇨🇳

Affiliated Cancer Hospital of Tianjin Medical University, Tianjin, Tianjin, China

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

First Posted Date
2022-11-21
Last Posted Date
2023-10-19
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
75
Registration Number
NCT05624099
Locations
🇨🇳

Fujian Cancer Hospital, Fuzhou, China

© Copyright 2024. All Rights Reserved by MedPath